ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026
In situ and localized primary invasive pregnancy-associated melanoma: Maternal and perinatal outcomes.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- In situ and localized primary invasive pregnancy-associated melanoma: Maternal and perinatal outcomes.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPregnancy-associated melanoma (PAM) is melanoma diagnosed during pregnancy or the 12 months postpartum. There is long-standing debate regarding the impact of pregnancy on melanoma prognosis. Previous studies have analysed pooled data from PAM diagnoses of all stages, so findings may not reflect outcomes associated with the diagnosis of in situ or localized PAM that are more commonly diagnosed than later stage PAM.
objectivesTo describe the incidence, perinatal and survival outcomes of in situ or localized primary invasive PAM (melanoma stages 0-II).
methodsA population-based retrospective cohort study in New South Wales (NSW), Australia was performed, comprising women who birthed between 1 January 1994 and 31 December 2013 and their babies, with mortality data available until September 2018. Women were grouped as gestational PAM (diagnosed with early-stage melanoma during pregnancy), postpartum PAM (diagnosed with early-stage melanoma within 1 year postpartum) or control (women who gave birth without a diagnosis of cancer). Perinatal outcomes were compared using generalized estimating equation models and mortality compared using Cox regression, Kaplan-Meier curves and the log-rank test.
resultsIn total, 1,785,876 pregnancies were identified, including 223 women (228 babies) with gestational PAM and 467 women (478 babies) with postpartum PAM. The incidence of in situ PAM increased 8.7% (95% CI: 4.0-13.5) per year between 2002 and 2013. The incidence of localized primary invasive PAM did not increase between 1994 and 2013. No significant maternal or neonatal morbidities were identified. Sixteen deaths were observed in women diagnosed with localized primary invasive PAM. The mortality rate for women with gestational PAM did not differ significantly from women with postpartum PAM (2.4/1000 person-years vs. 1.6/1000 person-years, p value = 0.394).
conclusionsDiagnosis of early PAM in pregnancy or postpartum is not associated with significant adverse outcomes for women or their babies. Early diagnosis remains important to ensure appropriate treatment and positive outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.